IFNA17

Summary

IFNA17 (interferon alpha 17, HGNC:5422) is a protein-coding gene on chromosome 9p21.3, encoding Interferon alpha-17 (P01571). Produced by macrophages, IFN-alpha have antiviral activities.

Predicted to enable cytokine activity and type I interferon receptor binding activity. Predicted to be involved in several processes, including lymphocyte activation involved in immune response; response to exogenous dsRNA; and type I interferon-mediated signaling pathway. Predicted to be located in extracellular region. Predicted to be active in extracellular space. Implicated in Crimean-Congo hemorrhagic fever and sarcoidosis.

Source: NCBI Gene 3451 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 42 total
• Druggable target: yes
• MANE Select transcript: NM_021268

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5422
Approved symbol	IFNA17
Name	interferon alpha 17
Location	9p21.3
Locus type	gene with protein product
Status	Approved
Aliases	LEIF2C1, IFN-alphaI
Ensembl gene	ENSG00000234829
Ensembl biotype	protein_coding
OMIM	147583
Entrez	3451

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000413767

RefSeq mRNA: 1 — MANE Select: NM_021268 NM_021268

CCDS: CCDS6500

Canonical transcript exons

ENST00000413767 — 1 exons

Exon	Start	End
ENSE00001770212	21227243	21228222

Expression profiles

Bgee: expression breadth tissue_specific, 1 present calls, max score 37.52.

Top tissues by expression

121 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ganglionic eminence	UBERON:0004023	37.52	silver quality
colonic epithelium	UBERON:0000397	37.20	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
hindlimb stylopod muscle	UBERON:0004252	32.15	gold quality
bone marrow	UBERON:0002371	31.74	gold quality
muscle tissue	UBERON:0002385	31.06	gold quality
sural nerve	UBERON:0015488	30.93	gold quality
stromal cell of endometrium	CL:0002255	29.87	gold quality
prefrontal cortex	UBERON:0000451	29.23	gold quality
liver	UBERON:0002107	28.33	gold quality
duodenum	UBERON:0002114	28.14	gold quality
urinary bladder	UBERON:0001255	28.04	gold quality
lymph node	UBERON:0000029	27.57	gold quality
tonsil	UBERON:0002372	27.05	gold quality
islet of Langerhans	UBERON:0000006	26.55	gold quality
vermiform appendix	UBERON:0001154	26.42	gold quality
blood	UBERON:0000178	26.38	gold quality
leukocyte	CL:0000738	26.10	gold quality
gall bladder	UBERON:0002110	25.98	gold quality
monocyte	CL:0000576	25.95	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	25.89	gold quality
placenta	UBERON:0001987	25.81	gold quality
muscle of leg	UBERON:0001383	24.87	gold quality
pancreas	UBERON:0001264	24.67	gold quality
primary visual cortex	UBERON:0002436	24.61	gold quality
superior frontal gyrus	UBERON:0002661	24.08	gold quality
frontal cortex	UBERON:0001870	24.07	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.15

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF3, IRF5, IRF7

miRNA regulators (miRDB)

22 targeting IFNA17, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-876-3P	98.76	68.23	945
HSA-MIR-4272	98.76	68.74	1810
HSA-MIR-323A-5P	98.59	65.13	651
HSA-MIR-4317	98.49	67.09	987
HSA-MIR-595	98.25	67.44	699
HSA-MIR-93-3P	98.15	66.65	1309
HSA-MIR-197-3P	98.09	69.23	1004
HSA-MIR-4659B-5P	98.03	66.84	979
HSA-MIR-4659A-5P	98.03	66.42	819
HSA-MIR-924	97.78	66.21	681
HSA-MIR-6894-3P	96.73	65.64	798
HSA-MIR-4636	91.87	64.93	40

Literature-anchored findings (GeneRIF, showing 6)

• The 184Ile homozygote of the IFNA17 gene may represent an important susceptibility biomarker for cervical cancer risk. (PMID:12490311)
• results do not support a role for a truncated IFNA17 as a candidate gene for multiple sclerosis pre-disposition in northern Sweden (PMID:17956450)
• We did not reproduce the associations previously noted with the TNF, IFNA10, IFNA17, and IFNG genes with pulmonary sarcoidosis. (PMID:20722470)
• results show that IFNA1 rs1332190 and IFNA17 rs9298814 SNPs may play an important role in Crimean-Congo hemorrhagic fever susceptibility (PMID:26694082)
• Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. (PMID:37020259)
• Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. (PMID:8668211)

Cross-species orthologs

34 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifnphi2	ENSDARG00000069012
danio_rerio	ifnphi3	ENSDARG00000070676
mus_musculus	Ifna13	ENSMUSG00000063376
mus_musculus	Ifna4	ENSMUSG00000070904
mus_musculus	Ifna12	ENSMUSG00000073811
mus_musculus	Ifna2	ENSMUSG00000078354
mus_musculus	Ifna16	ENSMUSG00000078355
mus_musculus	Ifna9	ENSMUSG00000095270
mus_musculus	Ifna1	ENSMUSG00000095498
mus_musculus	Ifna14	ENSMUSG00000095896
mus_musculus	Ifna15	ENSMUSG00000096011
mus_musculus	Ifna5	ENSMUSG00000096682
mus_musculus	Ifnab	ENSMUSG00000100079
mus_musculus	Ifna11	ENSMUSG00000100549
mus_musculus	Ifna7	ENSMUSG00000100713
mus_musculus	Ifna6	ENSMUSG00000101252
rattus_norvegicus		ENSRNOG00000071845
rattus_norvegicus	Ifna12l	ENSRNOG00000072681
rattus_norvegicus	Ifna16l1	ENSRNOG00000074841
rattus_norvegicus		ENSRNOG00000075722
rattus_norvegicus		ENSRNOG00000076372
rattus_norvegicus	Ifna4	ENSRNOG00000077072
rattus_norvegicus	Ifna2	ENSRNOG00000078310
rattus_norvegicus	Ifna5	ENSRNOG00000079725
rattus_norvegicus	Ifna1l1	ENSRNOG00000079800
rattus_norvegicus		ENSRNOG00000079804
rattus_norvegicus		ENSRNOG00000081823
rattus_norvegicus		ENSRNOG00000082441
rattus_norvegicus		ENSRNOG00000082845
rattus_norvegicus		ENSRNOG00000083047
rattus_norvegicus	Ifna1	ENSRNOG00000084770
rattus_norvegicus		ENSRNOG00000085373
rattus_norvegicus		ENSRNOG00000085882
rattus_norvegicus		ENSRNOG00000086565

Paralogs (16): IFNA6 (ENSG00000120235), IFNA8 (ENSG00000120242), IFNA21 (ENSG00000137080), IFNA5 (ENSG00000147873), IFNA16 (ENSG00000147885), IFNK (ENSG00000147896), IFNB1 (ENSG00000171855), IFNW1 (ENSG00000177047), IFNE (ENSG00000184995), IFNA10 (ENSG00000186803), IFNA2 (ENSG00000188379), IFNA1 (ENSG00000197919), IFNA7 (ENSG00000214042), IFNA14 (ENSG00000228083), IFNA13 (ENSG00000233816), IFNA4 (ENSG00000236637)

Protein

Protein identifiers

Interferon alpha-17 — P01571 (reviewed: P01571)

Alternative names: Interferon alpha-88, Interferon alpha-I’, Interferon alpha-T

All UniProt accessions (2): P01571, A0A7R8C355

UniProt curated annotations — full annotation on UniProt →

Function. Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Subcellular location. Secreted.

Similarity. Belongs to the type-I (or alpha/beta) interferon family.

RefSeq proteins (1): NP_067091* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000471	Interferon_alpha/beta/delta	Family
IPR009079	4_helix_cytokine-like_core	Homologous_superfamily

Pfam: PF00143

UniProt features (8 total): sequence conflict 3, disulfide bond 2, signal peptide 1, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P01571-F1	86.16	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 24–122, 52–162

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-912694	Regulation of IFNA/IFNB signaling
R-HSA-933541	TRAF6 mediated IRF7 activation
R-HSA-9705671	SARS-CoV-2 activates/modulates innate and adaptive immune responses
R-HSA-983231	Factors involved in megakaryocyte development and platelet production
R-HSA-9833109	Evasion by RSV of host interferon responses

MSigDB gene sets: 115 (showing top): REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_VIRUS, REACTOME_INNATE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_B_CELL_ACTIVATION, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, KEGG_AUTOIMMUNE_THYROID_DISEASE, HFH8_01, FOXJ2_01

GO Biological Process (12): adaptive immune response (GO:0002250), T cell activation involved in immune response (GO:0002286), B cell activation involved in immune response (GO:0002312), natural killer cell activation involved in immune response (GO:0002323), humoral immune response (GO:0006959), response to virus (GO:0009615), response to exogenous dsRNA (GO:0043330), defense response to virus (GO:0051607), type I interferon-mediated signaling pathway (GO:0060337), cellular response to virus (GO:0098586), defense response (GO:0006952), signal transduction (GO:0007165)

GO Molecular Function (3): cytokine activity (GO:0005125), type I interferon receptor binding (GO:0005132), cytokine receptor binding (GO:0005126)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Interferon Signaling	1
Interferon alpha/beta signaling	1
DDX58/IFIH1-mediated induction of interferon-alpha/beta	1
SARS-CoV-2-host interactions	1
Hemostasis	1
RSV-host interactions	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	4
lymphocyte activation involved in immune response	3
response to virus	2
T cell activation	1
B cell activation	1
natural killer cell activation	1
innate immune response	1
response to other organism	1
response to dsRNA	1
defense response	1
cellular response to type I interferon	1
interferon-mediated signaling pathway	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
cytokine receptor binding	1
protein-containing complex binding	1
signaling receptor binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1542 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFNA17	IFNAR1	P17181	948
IFNA17	IFNG	P01579	919
IFNA17	IL2	P01585	853
IFNA17	IFNAR2	P48551	830
IFNA17	IL6	P05231	805
IFNA17	IRF7	Q92985	800
IFNA17	TNF	P01375	797
IFNA17	TLR7	Q9NYK1	781
IFNA17	STAT1	P42224	775
IFNA17	CD4	P01730	756
IFNA17	TLR9	Q9NR96	745
IFNA17	TLR3	O15455	725
IFNA17	CD8A	P01732	720
IFNA17	RIGI	O95786	714
IFNA17	IL10	P22301	709

IntAct

14 interactions, top by confidence:

A	B	Type	Score
CABCOCO1	NME2P1	psi-mi:“MI:0914”(association)	0.530
ZNF586	IFNA13	psi-mi:“MI:0914”(association)	0.530
IFNA5	IFNA13	psi-mi:“MI:0914”(association)	0.530
IFNA13	IFNA21	psi-mi:“MI:0914”(association)	0.530
C16orf54	IFNA17	psi-mi:“MI:0914”(association)	0.530
LHFPL4	IFNA17	psi-mi:“MI:0914”(association)	0.530
M		psi-mi:“MI:0914”(association)	0.350

BioGRID (13): IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS)

ESM2 similar proteins: O46633, P01562, P01563, P01566, P01567, P01568, P01569, P01570, P01571, P01572, P05000, P05002, P05003, P05004, P05005, P05006, P05007, P05008, P05009, P05010, P05013, P05014, P05015, P07348, P07349, P07352, P09235, P15696, P28169, P28171, P28172, P32881, P49876, P49877, P49878, P49879, P56828, P56829, P56830, P56831

Diamond homologs: A7UHZ5, O46633, O77812, O97945, P01562, P01563, P01566, P01567, P01568, P01569, P01570, P01571, P01572, P01573, P01574, P01575, P01576, P01577, P01578, P05000, P05001, P05002, P05003, P05004, P05005, P05006, P05007, P05008, P05009, P05010, P05011, P05012, P05013, P05014, P05015, P06799, P07348, P07349, P07350, P07351

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

285 predictions. Top by Δscore:

Variant	Effect	Δscore
9:21228072:A:AC	donor_gain	0.7000
9:21227502:A:C	donor_gain	0.6900
9:21227546:A:AC	donor_gain	0.6500
9:21227389:A:AC	donor_gain	0.6300
9:21227424:T:C	donor_gain	0.6300
9:21227390:A:C	donor_gain	0.6200
9:21227470:CA:C	donor_gain	0.6100
9:21227437:AGTG:A	donor_gain	0.5900
9:21227440:G:A	donor_gain	0.5900
9:21227586:G:A	donor_gain	0.5900
9:21227727:T:TA	donor_gain	0.5800
9:21227929:T:TG	acceptor_gain	0.5600
9:21227890:T:TA	donor_gain	0.5500
9:21227983:T:TA	donor_gain	0.5400
9:21227639:T:TC	acceptor_gain	0.5300
9:21228194:TAGGC:T	donor_gain	0.5300
9:21228200:A:AC	donor_gain	0.5200
9:21228201:C:CC	donor_gain	0.5200
9:21227340:A:AC	donor_gain	0.5100
9:21227436:TAG:T	donor_gain	0.5100
9:21227612:T:A	donor_gain	0.5100
9:21227636:T:TC	acceptor_gain	0.5100
9:21227655:T:C	donor_gain	0.5100
9:21227761:T:TA	donor_gain	0.5100
9:21227636:T:C	acceptor_gain	0.5000
9:21227435:CTA:C	donor_gain	0.4900
9:21227747:C:CA	donor_gain	0.4900
9:21227790:C:A	donor_gain	0.4900
9:21227797:T:TA	donor_gain	0.4900
9:21227659:A:AC	donor_gain	0.4800

AlphaMissense

1248 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:21227733:G:C	F147L	0.943
9:21227733:G:T	F147L	0.943
9:21227735:A:G	F147L	0.943
9:21227997:A:C	F59L	0.937
9:21227997:A:T	F59L	0.937
9:21227999:A:G	F59L	0.937
9:21227682:C:A	W164C	0.890
9:21227682:C:G	W164C	0.890
9:21227901:G:C	F91L	0.851
9:21227901:G:T	F91L	0.851
9:21227903:A:G	F91L	0.851
9:21227674:A:T	V167D	0.826
9:21227874:C:A	W100C	0.825
9:21227874:C:G	W100C	0.825
9:21227998:A:C	F59C	0.802
9:21227670:T:A	R168S	0.798
9:21227670:T:G	R168S	0.798
9:21227827:A:G	L116P	0.794
9:21227905:A:G	L90P	0.784
9:21227713:A:G	L154P	0.777
9:21228019:C:G	C52S	0.772
9:21228020:A:T	C52S	0.772
9:21228020:A:G	C52R	0.770
9:21227684:A:G	W164R	0.768
9:21227684:A:T	W164R	0.768
9:21228018:G:C	C52W	0.768
9:21227717:A:C	Y153D	0.761
9:21227734:A:G	F147S	0.755
9:21227688:A:C	C162W	0.746
9:21227669:C:G	A169P	0.742

dbSNP variants (sampled 300 via entrez): RS1001108525 (9:21228359 GTT>G), RS1001455121 (9:21228497 ATG>A), RS1002265079 (9:21228555 A>C), RS1003269903 (9:21229492 A>T), RS1004332482 (9:21228806 A>C,G), RS1007406819 (9:21229430 T>A,C), RS1007871494 (9:21229289 A>C), RS1008924716 (9:21227323 G>A,C), RS1009237920 (9:21229314 G>C,T), RS1009520950 (9:21229455 T>C), RS1010984985 (9:21227508 G>C,T), RS10117962 (9:21227943 G>A,T), RS1011993149 (9:21230144 G>A), RS1013160533 (9:21227064 T>A), RS1013601595 (9:21228382 T>C,G)

Disease associations

OMIM: gene MIM:147583 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST011096_25	Systemic lupus erythematosus	6.000000e-08

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3856161 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

6 total (human), top 6 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
apocarotenal	increases expression	1
hydroxyhydroquinone	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Antirheumatic Agents	decreases expression	1
beta Carotene	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.